Author Archives: Ana Pena, PhD

Investigational Therapy Tofersen Can Reduce Toxic SOD1 Protein Levels in Familial ALS Patients, Study Shows

Biogen’s investigational therapy tofersen can significantly reduce toxic levels of SOD1 protein and may slow disability progression in people with familial amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, interim study results show. The positive data from a Phase 1/2 clinical trial support advancing the experimental compound into Phase 3…